echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Data on premenopausal patients in the second-generation breast cancer polygenic test EndoPredict were officially released at the CCR

    Data on premenopausal patients in the second-generation breast cancer polygenic test EndoPredict were officially released at the CCR

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Dr.


    The study abstract was first published by Dr.


    The study suggests that in the overall population, 65% of patients assessed as low-risk EPclin, 97% of 10-year DRFS, and 76% of high-risk patients with DRFS;

    In the lymph node-positive subgroup, EPclin was assessed as low-risk for 19% of patients and 100% of 10-year DRFS, demonstrating that EndoPredict can accurately prognosis in premenopausal patient populations regardless of whether nodes are negative or positive


    In addition, the results of another exploratory subgroup analysis of the study showed that in patients assessed as low-risk in EPclin, patients with 10-year DRFS were similar, less than 5%,


    In response to the study's published data, Dr.


    Based on this, Dr.


    Dr.


    The study abstract was first published by Dr.


    The study suggests that in the overall population, 65% of patients assessed as low-risk EPclin, 97% of 10-year DRFS, and 76% of high-risk patients with DRFS;

    In the lymph node-positive subgroup, EPclin was assessed as low-risk for 19% of patients and 100% of 10-year DRFS, demonstrating that EndoPredict can accurately prognosis in premenopausal patient populations regardless of whether nodes are negative or positive


    In addition, the results of another exploratory subgroup analysis of the study showed that in patients assessed as low-risk in EPclin, patients with 10-year DRFS were similar, less than 5%,


    In response to the study's published data, Dr.


    Based on this, Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.